BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36286264)

  • 1. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis.
    Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH
    Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
    Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
    Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
    Damrauer SM; Chaudhary K; Cho JH; Liang LW; Argulian E; Chan L; Dobbyn A; Guerraty MA; Judy R; Kay J; Kember RL; Levin MG; Saha A; Van Vleck T; Verma SS; Weaver J; Abul-Husn NS; Baras A; Chirinos JA; Drachman B; Kenny EE; Loos RJF; Narula J; Overton J; Reid J; Ritchie M; Sirugo G; Nadkarni G; Rader DJ; Do R
    JAMA; 2019 Dec; 322(22):2191-2202. PubMed ID: 31821430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I
    Hendren NS; De Lemos JA; Berry JD; Kozlitina J; Saelices L; Ji AX; Shao Z; Liu CF; Garg S; Farr MA; Drazner MH; Tang WHW; Grodin JL
    Amyloid; 2024 Jun; 31(2):124-131. PubMed ID: 38445629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
    Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
    J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of
    Lopes LR; Futema M; Akhtar MM; Lorenzini M; Pittman A; Syrris P; Elliott PM
    Amyloid; 2019 Dec; 26(4):243-247. PubMed ID: 31554435
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
    Haring B; Hunt RP; Shadyab AH; Eaton C; Kaplan R; Martin LW; Panjrath G; Kuller LH; Assimes T; Kooperberg C; Wassertheil-Smoller S
    JACC Heart Fail; 2023 Sep; 11(9):1189-1199. PubMed ID: 36930136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans.
    Jacobson DR; Alexander AA; Tagoe C; Buxbaum JN
    Amyloid; 2015; 22(3):171-4. PubMed ID: 26123279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
    Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
    Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
    Manral P; Reixach N
    Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
    Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
    Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis.
    Thenappan T; Fedson S; Rich J; Murks C; Husain A; Pogoriler J; Anderson AS
    Amyloid; 2014 Jun; 21(2):120-3. PubMed ID: 24818650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
    Parker MM; Damrauer SM; Tcheandjieu C; Erbe D; Aldinc E; Hawkins PN; Gillmore JD; Hull LE; Lynch JA; Joseph J; Ticau S; Flynn-Carroll AO; Deaton AM; Ward LD; Assimes TL; Tsao PS; Chang KM; Rader DJ; Fitzgerald K; Vaishnaw AK; Hinkle G; Nioi P
    Sci Rep; 2021 Jun; 11(1):11645. PubMed ID: 34079032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.
    Reddi HV; Jenkins S; Theis J; Thomas BC; Connors LH; Van Rhee F; Highsmith WE
    J Mol Diagn; 2014 Jan; 16(1):68-74. PubMed ID: 24184229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR; Powers ET; Kelly JW
    Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
    Kozlitina J; Garg S; Drazner MH; Matulevicius SA; Ayers C; Overton J; Reid J; Baras A; Rao K; Pandey A; Berry J; de Lemos JA; Grodin JL
    J Card Fail; 2022 Mar; 28(3):403-414. PubMed ID: 34634447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.